Clinical trial · Interventional

Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma

NCT06932861CI-TRIAL-00088788not yet recruitingEarly Phase 1ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Rhabdomyosarcoma	Rhabdomyosarcoma	ONTOLOGY_EXACT	0.90

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
mRNA Tumor Vaccine Therapy	Biological	—	UNRESOLVED

Design

Arms and outcomes

Arms (1)

type
EXPERIMENTAL
label
Vaccine arm
interventionNames
1. Biological: mRNA Tumor Vaccine Therapy

Primary outcomes (1)

measure
Adverse Event
timeFrame
From the first administration of the study drug until the occurrence of death, loss to follow-up, withdrawal of informed consent, initiation of a new anti-tumor therapy, or 21 days after the last dose, whichever comes first.

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 6 Years

Show eligibility criteria text

Inclusion Criteria:

1. Diagnosed with rhabdomyosarcoma confirmed by pathological or molecular testing;
2. Age ≥ 6 years;
3. No known effective treatment available or no treatment proven to prolong survival with an acceptable quality of life;
4. Expected survival time greater than 6 months;
5. ECOG performance status score of 0-1; -

Exclusion Criteria:

* 1.History of or concurrent with other untreated malignant tumors, except for previously cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and superficial bladder cancer; 2.History of or current active autoimmune diseases. 3.Has uncontrolled cardiovascular diseases.

References

Publications (0)

Data not yet available

No reference posted for this study.